Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 473Neoplasms 290Breast Neoplasms 277Colorectal Neoplasms 223Neoplasm Metastasis 187Prostatic Neoplasms 168Ovarian Neoplasms 163Lung Neoplasms 154Multiple Myeloma 152Recurrence 132Melanoma 116Pancreatic Neoplasms 114Squamous Cell Carcinoma of Head and Neck 104Endometrial Neoplasms 98Stomach Neoplasms 97Leukemia, Myeloid, Acute 95Small Cell Lung Carcinoma 84Leukemia, Lymphocytic, Chronic, B-Cell 83Lymphoma, Non-Hodgkin 81Triple Negative Breast Neoplasms 80Carcinoma, Renal Cell 79Carcinoma, Hepatocellular 77Urinary Bladder Neoplasms 75Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 64Advanced Solid Tumors 63Lymphoma 60Glioblastoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 55Head and Neck Neoplasms 53

Interventions

regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Malignant Tumors × 90 days × Clear all
NCT06246643 2026-05-19

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Bayer

Phase 2 Active not recruiting
13 enrolled

Solid Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡